MOST-ExpressNCT07936422
A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Objective Response Rate at 18 weeks (ORR-18W)
Timeframe: 18 weeks after treatment start
Secondary (7)
Duration of Response (DoR)
Progression Free Survival (PFS)
Progression Free Rate at 18W (PFR-18W)
Overall Survival (OS)
Safety as per NCI-CTCAE V6.0
Show 2 moreShow less
EQ-5D-5L questionnaire
Length of hospital stays (LOS) including acute care hospitalizations? home care hospitalizations and follow-up and rehabilitation care
Arms and interventions
Trastuzumab deruxtecanExperimental
HER2-targeted antibody-drug conjugate
Drugs: Trastuzumab Deruxtecan for Injection (T-DXd)
Sites
6 sites in 1 country